{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:39Z","timestamp":1790873919912,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Portal vein tumor thrombus (PVTT) is a common complication and an obstacle to treatment, with a high recurrence rate and poor prognosis. There is still no global consensus or standard guidelines on the management of hepatocellular carcinoma (HCC) with PVTT. Increasing evidence suggests that more aggressive treatment modalities, including transarterial chemoembolization, radiotherapy, targeted therapy, and various combination therapies, may improve the prognosis and prolong the survival of advanced hepatocellular carcinoma (aHCC) patients with PVTT. We aim to comprehensively review and compare the efficacy and safety of these advanced options for aHCC with PVTT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive literature search was conducted on PubMed and EMBASE for phase II or III randomized controlled trials (RCTs) investigating multimodality treatments for aHCC with PVTT. Kaplan\u2013Meier curves for overall survival (OS) and progression-free survival were constructed to retrieve individual patient-level data to strengthen the comparison of the benefits of all multimodality treatments of interest. Each study was pooled in a fixed-effects network meta-analysis (NMA). We also conducted subgroup analyses using risk ratios extracted from each study, including viral etiology, Barcelona Clinic Liver Cancer (BCLC) staging, alpha-fetoprotein (AFP) levels, macrovascular invasion or portal vein tumor thrombosis, and extrahepatic spread. Multimodality treatments were ranked using SUCRA scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 15 randomized controlled trials with 16 multimodality regimens that met the inclusion criteria. Among them, 5,236 patients with OS results and 5,160 patients with PFS results were included in the analysis. The hepatic arterial infusion chemotherapy of fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) showed OS and PFS benefits over all the other therapies. In terms of OS, HAIC-FO, nivolumab, and TACE+Len were superior to sorafenib, lenvatinib, and donatinib monotherapies, as well as HAIC-FO+Sor. In terms of PFS, TACE+Len showed better benefits than lenvatinib, donatinib, and tremelimumab+durvalumab. A low heterogeneity (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> &amp;lt; 50%) and consistency were observed. The SUCRA score for OS ranked HAIC-FO+sorafenib as the best treatment option among all multimodality treatments in hepatitis B, MVI, or PVTT with EHS and AFP 400 \u03bcg\/L subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HAIC-FO and HAIC-FO+sorafenib are statistically better options for unresectable hepatocellular carcinoma with PVTT among the multimodality treatments, and their effective and safe implementation may provide the best outcomes for HCC-PVTT patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1344798","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T07:48:47Z","timestamp":1708069727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"John Hang","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Yau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W. C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes L. F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"B1","unstructured":"Liver cancer: statistics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12817","article-title":"Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.2.115","article-title":"New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis","volume":"21","author":"Woo","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00071","article-title":"New evidence and perspectives on the management of hepatocellular carcinoma with portal vein tumor thrombus","volume":"5","author":"Yin","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"B5","article-title":"Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma","volume":"13","author":"Sun","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2391","article-title":"Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma","volume":"44","author":"Huang","year":"2012","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.124","article-title":"Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation","volume":"31","author":"Tan","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13988","article-title":"Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse","volume":"39","author":"M\u00e4hringer-Kunz","year":"2019","journal-title":"Liver Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10032-2","article-title":"Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30490","article-title":"An eastern hepatobiliary surgery hospital\/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study","volume":"69","author":"Zhang","year":"2019","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2021.01173","article-title":"The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus","volume":"15","author":"Qiu","year":"2021","journal-title":"Biosci Trends."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1186\/s12885-019-6198-8","article-title":"Randomized, phase III trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial","volume":"19","author":"Kondo","year":"2019","journal-title":"BMC Cancer."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: A randomized trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jimed.2019.07.005","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma","volume":"2","author":"Zhao","year":"2019","journal-title":"J Interv Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.729764","article-title":"Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0192","article-title":"Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma","volume":"13","author":"Liu","year":"2021","journal-title":"Immunotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma, Nat","volume":"15","author":"Llovet","year":"2018","journal-title":"Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e934475","DOI":"10.12659\/MSM.934475","article-title":"Editorial: review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B26","volume-title":"Review Manager (RevMan) computer program, version 5.4.1 Copenhagen: The Cochrane Collaboration","year":"2020"},{"key":"B27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPD from KM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"B30","unstructured":"Choosing effect measures and computing estimates of effect\n            HigginsJPT\n            LiT\n            DeeksJJ\n            HigginsJPT\n            ThomasJ\n            ChandlerJ\n          CochraneCochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)2022"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-018-3638-0","article-title":"Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"82","author":"Choi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"key":"B38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"A Microsoft-excel-based tool for running and critically appraising network meta-analyses\u2013an over view and application of NetMetaXL","volume":"3","author":"Brown","year":"2014","journal-title":"Syst Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8383","article-title":"Identifying inconsistency in network meta-analysis: Is the net heat plot a reliable method","volume":"38","author":"Freeman","year":"2019","journal-title":"Stat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study","volume":"127","author":"Ding","year":"2021","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010096","article-title":"Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus: A systematic review and meta-analysis","volume":"30","author":"Deng","year":"2023","journal-title":"Curr Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"110797","DOI":"10.1016\/j.biopha.2020.110797","article-title":"The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma","volume":"132","author":"Wang","year":"2020","journal-title":"BioMed Pharmacother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e2000055","DOI":"10.1002\/adma.202000055","article-title":"Designing stimuli-responsive upconversion nanoparticles that exploit the tumor microenvironment","volume":"32","author":"Ovais","year":"2020","journal-title":"Adv Mater"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat\u00a0Rev Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour Microenvironment","volume":"17","author":"Sharonov","year":"2020","journal-title":"Nat\u00a0Rev Clin Oncol"},{"key":"B53","first-page":"190","article-title":"Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma","volume":"15","author":"Thomas","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5582\/bst.2022.01044","article-title":"Use of chemotherapy to treat hepatocellular carcinoma","volume":"16","author":"Hou","year":"2022","journal-title":"Biosci Trends"},{"key":"B55","article-title":"Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials","volume":"26","author":"Pan","year":"2021","journal-title":"Front Biosci (Landmark Ed)."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"Marinelli","year":"2022","journal-title":"J\u00a0Immunother Cancer."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13361","article-title":"Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease","volume":"17","author":"Choi","year":"2021","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1344798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T07:48:54Z","timestamp":1708069734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1344798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":57,"alternative-id":["10.3389\/fonc.2024.1344798"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1344798","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"article-number":"1344798"}}